Casualty Of Change? Innovent/Lilly’s Chinese PD-1 Inhibitor Sintilimab Falls Hard At US FDA Panel
Executive Summary
Advisory committee says additional trials needed to demonstrate applicability of ORIENT-11 results to US population; in opting to seek approval only with Chinese data, Innovent said it relied on 2019 comments by FDA’s Richard Pazdur, but the oncology center head said therapeutic and societal changes have caused an evolution in the agency’s thinking.
You may also be interested in...
Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships
Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.
BeiGene Among Chinese Firms Eyeing Less Crowded SCLC Sector In US Trials
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
Chinese PD-1s Eye US Approvals Despite Lack Of Action Dates
Although Novartis/BeiGene’s tislelizumab and Coherus /Junshi’s toripalimab have not received a new Prescription Drug User Fee Act (PDUFA) decision date for their biologics license applications in the US, the companies remain hopeful that potential approvals will be granted in the third quarter at the earliest.